3 Articles found

Metafora Biosystems articles

First patient inclusion of the METAglut1 study

The METAglut1 study is a prospective study to validate the diagnostic performance of the METAglut1 test in patients clinically compatible with GLUT1 Glucose Deficiency Syndrome (GLUT1-DS) or « DE VIVO Disease ».It will be conducted in about 40 French centers and plans to include between 2500 and 3000 patients over a period of 30 months.
This study has received the support of the European Commission under the H2020 program.

Sep. 23, 2018

Metafora and collaborators publishes a paper in Annals of Neurology

METAFORA is proud to announce that its first publication related to the use of its technology to diagnose a rare metabolic disease rapidly and efficientely has been accepted for publication in the reference journal, Annals of Neurology. The test is being commercialized under the name METAglut1 and was recently CE marked. It is available in France through the CERBA network of clinical testing laboratories.

The Article

Teams from the AP-HP (Paris public hospital

Jul. 19, 2017

Our innovative technology becomes available for patients

Following a successful fundraising in Q4 2016, METAFORA achieves an important milestone by announcing, in partnership with CERBA Healthcare, the availability of the METAglut1 blood test to diagnose the GLUT1 deficiency syndrome (GLUT1 DS). Through METAglut1, our disruptive technology becomes available, for the first time, to patients.

De Vivo’s disease (the other name of GLUT1 DS) is affecting mainly children and is very debilitating. This is due to a defect in the expression of

Feb. 6, 2017